Month: September 2021

We are professional 2-Bromo-N,N-dimethylaniline manufacturer and N,N-dimethyl-o-bromoaniline supplier in China, We offer quality 2-Bromo-N,N-dimethylaniline you can fully trust, also we have India factory and producer of 2-Bromo-N,N-dimethylaniline,Pls send inquiry of 2-Bromo-N,N-dimethylaniline CAS:698-00-0 to info@nbinno.com if you have any interests, thank you!


Related News: Soliris would need a “substantial discount” to reach a more appropriate price, according to its report. Using the widely leveraged measure for disease burden known as quality-adjusted life year (QALY), ICER calculated a range of $6,900 to achieve $50,000 per QALY to $25,700 to hit $200,000 per QALY.5,5′-disulfanediyldipentanal manufacturer For Franco Stevanato, tapping public markets will give the company the freedom to keep innovating as it enters the next chapter of its 70-plus-year history. N-[3,5-Bis(trifluoromethyl)benzyl]-2-(hydroxymethyl)-4-phenyl-3-q uinolinecarboxamide supplier Anifrolumab is a fully human monoclonal antibody that binds to subunit 1 of the type I interferon receptor, blocking the activity of type I interferons. 1-(4,6-diamino-pyrimidin-2-ylsulfanyl)-propan-2-one manufacturer The short answer? Expect slower growth going forward.

Synonym:
Tert-Butyl N-Acetate
1,1-Dimethyl Acetate
2-Methyl-2-Propanyl Acetate
CAS Number: 540-88-5
 
Chemical & Physical Properties
Density: 0.862
Boiling Point: 98 ºC
Melting Point: -62°C
Molecular Formula: C₆H₁₂O₂
Molecular Weight: 116.158
Flash Point: 15 ºC
Exact Mass: 116.083733
PSA: 26.30000
LogP: 1.40
Vapour Pressure: 40.6±0.2 mmHg at 25°C
Index of Refraction: 1.385-1.387
Water Solubility: insoluble
 
Specification
Appearance: Colorless clear liquid
Assay: ≥99.0%
Acid Value(mgKOH/g): ≤2.0
Water: ≤0.1%
 
Application
Used as a solvent for gasoline anti-vibration additives, chemical solvents, nitrocellulose, etc.
 
Storage
Store in a cool, dry place away from light. Packed in cardboard drums or cartons lined with plastic bags.
170kg/drum, can also be designed according to customer requirements. 



We are professional tert-Butyl acetate manufacturer and 2-Methyl-2-Propanyl Acetate supplier in China, We offer quality Tert-Butyl N-Acetate you can fully trust, also we have India factory and producer of Tert-Butyl N-Acetate,Pls send inquiry of 1,1-Dimethyl Acetate CAS:540-88-5 to info@nbinno.com if you have any interests, thank you!


Related News: Stem cell transplants from matched, related donors can be effective, but most patients don’t have such donors available to them. Methanimidamide, N-ethoxy-N’-(4-ethoxy-3-ethylphenyl)-, ethanedioate(1:1) manufacturer Dr. Elsie Melsopp, Head of Solids Formulations for Alcami, says the company successfully helped a client overcome an API supply shortage using Quality by Design (QbD) studies to successfully formulate an orphan drug product. tetratert-butylazanium,chloride supplier The BetterUp experience, which currently consists of one-to-one coaching, counseling, mentorship, group sessions, and interactive content – was built by a team of the world’s leading PhDs and scientists and science advisors including Adam Grant, Martin Seligman, Shawn Achor, Josh Bersin, Robin Ely, and Quinetta Roberson. 2-(2-Imino-benzothiazol-3-yl)-1-(3-methanesulfinyl-4-methyl-phenyl)-ethanone; hydrobromide manufacturer After the IPO, he now owns a 53% stake, worth $3.1 billion, plus roughly $100 million in cash and other investments, including a winery in northeastern Italy. His sons Franco and Marco (the company’s vice chairman) each own 12% stakes worth about $730 million apiece.

Synonym: N-Decyl-N,N-Dimethyldecan-1-Aminium Chloride
CAS Number: 7173-51-5
EINECS: 230-525-2
 
Chemical & Physical Properties
Density: 0.95 g/cm³ (20ºC)
Molecular Formula: C₂₂H₄₈ClN
Molecular Weight: 362.076
Exact Mass: 361.347534
LogP: 4.34820
 
Specification
Appearance : Colorless to pale yellow clear liquid
Active Assay : 80%±2%
PH : 5-9
Content of Free amine : ≤1.5%
Color (Pt-Co) : ≤150#
 
Application
DDAC is widely used in oil field sterilization, medicine and hygiene, industrial circulating water sterilization and algae removal, oil field drilling and other fields. Its sterilization effect is better than the most widely used dodecyl dimethyl benzyl ammonium chloride. It can be used as a bactericide and bactericidal algicide in oilfield water injection and industrial circulating cooling water systems. When used as a bactericide for hard surface treatment, it can be used in combination with chlorine dioxide.
 
DDAC is a kind of wool moth agent, which can control insect diseases, and is used as a disinfectant and bactericide in medicine, health and civil use.
 
Package and Storage
180kgs/plastic drum. Should be stored in a sealed container in a cool and dry place. If the material freezes, it should be gently heated and stirred before use to ensure that the material is uniform.
 
Note: Avoid compatibility with anionic surfactants, dyes or auxiliaries.It is easy to absorb water and should be stored properly.



We are professional Didecyl Dimethyl Ammonium Chloride manufacturer and N-Decyl-N,N-Dimethyldecan-1-Aminium Chloride supplier in China, We offer quality N-Decyl-N,N-Dimethyldecan-1-Aminium Chloride you can fully trust, also we have India factory and producer of Didecyl Dimethyl Ammonium Chloride,Pls send inquiry of Didecyl Dimethyl Ammonium Chloride CAS:7173-51-5 to info@nbinno.com if you have any interests, thank you!


Related News: Over the past few years, China has been offering AstraZeneca bragging rights. But the company’s business in the country is coming to a turning point after being exposed to the government’s price-cutting scheme and local competition—and investors have caught wind.bis(3-hydroxy-2,3-dimethylbutan-2-yl) (hydroxy(phenyl)methyl)phosphonate manufacturer So-called “off” periods occur when a Parkinson’s patient has difficulty moving about and occur when the effect of the last dose of another common Parkinson’s drug, known as levodopa, wears off. Uracil phosphoribosyltransferase (Mycoplasma mobile strain 163Kgene upp) supplier GEM has also partnered with Good360 & Walmart to ensure that every relocated family has move in essentials like bedding, towels, small appliances, tableware, cutlery, glassware and cookware. In addition, each relocated family in the program will receive our GEM Bstrong, Good360, and Walmart ‘Welcome Home Kits’ consisting of new sheets, towels, silverware, pots and pans sets, small appliances and basic move in goods. Transportation of goods provided by GEM transportation partner UC Group (www.groupncs.com). 2H-Pyrrole, 3,4-dihydro-2-methyl-2,3-diphenyl- manufacturer ChenMed, which presently operates more than 80 Chen, Dedicated and JenCare Senior Medical Centers in 12 states, has successfully vaccinated 100 percent of doctors and staff at over 70 of its practices by educating and encouraging care team members and patients alike through its ongoing and multifaceted VaxTheNation® initiative.

Synonym: Polyhexamethylene Biguanide Hydrochloride
CAS Number: 32289-58-0
EINECS: 1308068-626-2
 
Chemical & Physical Properties
Molecular Formula: (C₈H₁₇N₅)n.xClH
Molecular Weight: 213.32312
 
Specification
Appearance: Colorless or light-yellow solid
Active ingredient: ≥99%
Water soluble: 100% soluble
Odor: Light ammonia smell
Moisture content: ≤0.5%
Water insoluble matter: ≤0.1%
PH in 1% aqueous solution: >4
Ash: 0.05%
 
Application
PHMB is an environmental-friendly Cationic Polymer. This chemical is water soluble and the aqueous solution is colorless and odorless, broad-spectrum, high-efficiency,low toxicity, good stability, non-flammable and non-explosive. Normally non-corrosive to stainless steel, stainless copper, carbon steel, wood, plastic, etc. PHMB is a high molecular polymer, which is not easily absorbed by tissues, has no corrosive effect, has good stability and is easy to rinse, good biocompatibility. Vitro studies have shown that it is non-toxic to human cells, and the in vivo irritation test results of rabbit and human hand skin show that it has no irritation to animal and human skin. It is widely used in textile printing and dyeing, animal husbandry, aquaculture, medical sterilization and daily disinfection.
 
Package and Storage
20kgs/drum. Store in a cool, dry, well-ventilated warehouse. Keep away from fire and heat
sources. Prevent direct sunlight. The package is sealed and kept away from moisture. Store separately from oxidizers and flammable materials. Do not store them together. The storage area should be equipped with suitable materials to contain the leakage.



We are professional Poly (Hexamethylene Biguanide) Hydrochloride (PHMB) manufacturer and Polyhexamethylene Biguanide Hydrochloride supplier in China, We offer quality Poly (Hexamethylene Biguanide) Hydrochloride (PHMB) you can fully trust, also we have India factory and producer of Polyhexamethylene Biguanide Hydrochloride,Pls send inquiry of Polyhexamethylene Biguanide Hydrochloride CAS:32289-58-0 to info@nbinno.com if you have any interests, thank you!


Related News: J&J’s shot generates roughly 8 GBS cases per million vaccinated people, far higher than just a single case reported per million among mRNA recipients, CDC reported. 5-amino-1,2,7,8-tetrahydro-6H-benzo[6,7]cyclohepta[1,2-d]furo[2,3-b]pyridine manufacturer But when it came to deciding on whether Americans with compromised immune systems should get an extra dose of any COVID-19 vaccine, the CDC said it would need to wait for the FDA to give its regulatory thumbs up first. That could come either through amending its emergency use nods or awarding full approvals. arsenic oxide trichloride dimer supplier In the trial, 362 eligible patients were randomised (1:1) and received a fixed-dose intravenous infusion of 300mg anifrolumab or placebo every four weeks. 9-((1s,4s)-4-aminocyclohexyl)-N8-(2-fluorophenyl)-N2-(4-methoxyphenyl)-9H-purine-2,8-diamine manufacturer Standard therapy consisted of oral corticosteroids (OCS), antimalarials and immunosuppressants (methotrexate, azathioprine or mycophenolate mofetil, known as MMF).

We are professional (S)-(-)-4-Isopropyl-2-oxazolidinone manufacturer and (S)-4-Isopropyl-2-oxazolidinone supplier in China, We offer quality (S)-(−)-4-Isopropyl-2-oxazolidinone you can fully trust, also we have India factory and producer of (S)-(-)-4-Isopropyl-2-oxazolidinone,Pls send inquiry of (S)-(-)-4-Isopropyl-2-oxazolidinone CAS:17016-83-0 to info@nbinno.com if you have any interests, thank you!


Related News: The European Commission (EC) has approved MSD and Bayer’s Verquvo for the treatment of symptomatic chronic heart failure in patients with reduced ejection fraction.5-Triisopropylsilanyl-furan-2-carbaldehyde manufacturer Type I interferons such as IFN-alpha, IFN-beta and IFN-kappa are cytokines involved in regulating the inflammatory pathways implicated in lupus. Hexadecyl-dimethyl-(1-phenyl-ethyl)-ammonium; bromide supplier Over the past two to three years, VBP has become “quite a challenge,” AZ’s international and China market chief Leon Wang said on the call. In response, the company has resorted to multichannel marketing, turning to the retail pharmacy market to soften the blow of tender losses. 7-[4-(2-butoxyethoxy)phenyl]-1-propyl-N-[6-[[(1-propylimidazol-2-yl)methyl]sulfinyl]-3-pyridinyl]-2,3-dihydro-1-benzazepine-4-carboxamide manufacturer Operating more than 80 primary care medical practices for diverse populations of seniors, ChenMed results consistently include up to 75 percent drops in emergency room visits, plus 30 to 50 percent reductions for in-patient hospital admissions. A Fortune 2020 Change the World” company, ChenMed brands include Chen Senior Medical Center, Dedicated Senior Medical Center and JenCare Senior Medical Center.
Medallia (NYSE: MDLA) is the pioneer and market leader in Experience Management. Medallia’s award-winning SaaS platform, the Medallia Experience Cloud, leads the market in the understanding and management of experience for customers, employees and citizens.
Medallia captures experience signals created on daily journeys in person, digital and IoT interactions and applies proprietary AI technology to reveal personalized and predictive insights that can drive action with tremendous business results. Using Medallia Experience Cloud, customers can reduce churn, turn detractors into promoters and buyers, and create in-the-moment cross-sell and up-sell opportunities, providing clear and potent returns on investment
QYNAPSE Inc., a medical technology company commercializing an AI-powered and proprietary neuroimaging software platform, is attending the Alzheimer’s Association International Conference 2021 (AAIC) on July 26-30, 2021 in Denver, USA and online, and will present two poster presentations on QyScore®, it’s groundbreaking neuroimaging analysis platform for both clinical routine and clinical trial settings.
Powered by the robust technology and designed to seamlessly integrate with existing workflows, QyScore® which is both FDA-cleared and CE-marked, provides insightful layers of precision for the analysis of brain MRIs, offering the potential to reduce the time to diagnosis and more precisely measure disease progression for Alzheimer’s and other central nervous system (CNS) diseases.
“We are very pleased to attend AAIC in-person in Denver this year to present and discuss our latest advances with the neuroscience community. We have made tremendous progress in 2021 towards expanding the commercialization of QyScore® into new global markets and to strengthen our clinical trial offering.
Qynapse is dedicated to bring ground-breaking peace of mind to the global fight against Alzheimer’s disease, by continuing to support clinicians around the world and build new tools that will support the ongoing care of patients in light of new disease-modifying treatment options for patients.” said Matt Ullum, CPA, MBA, Chief Commercial Officer at Qynapse.
Rapid reduction and sustained normalization of heparan sulfate in CSF demonstrated robust and durable CNS activity with intravenous administration, and enhanced peripheral activity with reductions in urine and serum heparan sulfate after switching from standard-of-care idursulfase
Global Impression of Change scales data suggested clinical improvement in overall MPS II symptoms, cognitive abilities, behavior, and physical abilities
Exploratory biomarker data demonstrated reductions in CSF lysosomal lipid biomarkers that are consistent with improved lysosomal function; and high variability in exploratory biomarker Nf-L was observed pre- and post-treatment
Safety profile with up to 43 weeks of dosing was consistent with standard of care enzyme replacement therapy with infusion-related reactions being the most frequently observed adverse events
Based on these data, Denali is accelerating efforts to initiate a pivotal Phase 2/3 study in 1H 2022
SOUTH SAN FRANCISCO, Calif., July 25, 2021 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced additional positive interim data from a Phase 1/2 study evaluating ETV:IDS (DNL310), an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system (CNS) and peripheral manifestations of Hunter syndrome (MPS II).
The interim results being presented today at MPS 2021, the 16th International Symposium on MPS and Related Diseases, include safety data up to Weeks 43 and 25 from Cohorts A and B, respectively, 6-month biomarker data from Cohort A and up to 3-month biomarker data from Cohort B. Denali Management will host a webinar today for analysts and investors beginning at approximately 11:30 a.m. Eastern Time.
“The longer-term safety data and 6-month biomarker data on DNL310 from Cohort A continue to demonstrate durability of effect with CNS impact, improved peripheral activity after switching from standard of care, and a safety profile consistent with standard of care enzyme replacement therapy,” said Carole Ho, M.D., Denali’s Chief Medical Officer.
“We are also encouraged by initial indications of improved clinical symptoms and function reported by investigators and parents in all five patients enrolled in Cohort A. In addition, this is the first time we are sharing data from Cohort B, which is designed to inform dose selection, and exploratory biomarker data demonstrate activity of DNL310 across all dose regimens.
Based on these data, we are accelerating our efforts to initiate a pivotal Phase 2/3 study of DNL310 in the first half of 2022 and to begin enrolling Cohort C in the Phase 1/2 study to further investigate clinical endpoints.”
This interim analysis of the Phase 1/2 study included data on five patients enrolled in Cohort A and 12 patients enrolled in Cohort B. All patients have neuronopathic MPS II disease except for one patient with non-neuronopathic MPS II disease in Cohort B.
The median age of patients is 6 years in both cohorts, with the youngest patients aged 5 and 2 in Cohorts A and B, respectively. All patients received weekly intravenous doses of DNL310 after switching from idursulfase enzyme replacement therapy on Day 1 of the study.
Data being presented include safety data up to Weeks 43 and 25 from Cohorts A and B, respectively; 6-month and up to 3-month biomarker data from Cohorts A and B, respectively; and exploratory clinical Global Impression of Change data from Cohort A up to Week 24.
Results across Cohorts A and B showed that, following the switch from idursulfase to DNL310, the levels of heparan sulfate in cerebrospinal fluid (CSF) normalized in all patients analyzed (n=15), with rapid response observed in most patients (n=12) by Week 7, which is consistent with crossing of the BBB by DNL310 and activity in tissues of the CNS.
Rapid normalization of CSF heparan sulfate at low dose regimens suggest that BBB crossing with Denali’s Transport Vehicle (TV) was robust and efficient. Furthermore, the observed decline in urine and serum heparan sulfate was consistent with improved peripheral activity with DNL310.
Exploratory clinical data suggest improved clinical symptoms and function for all five patients enrolled in Cohort A as reported by investigators and parents. Based on Global Impression of Change scales [Clinician Global Impression of Change (CGI-C) and Parent Global Impression of Change (PGI-C)], which are standardized assessment scales used to measure change, the data showed clinical improvement in overall MPS II symptoms, cognitive abilities, behavior, and physical abilities.
Exploratory lysosomal lipid data showed reductions, which are consistent with improved lysosomal function: 10 of 15 patients across Cohorts A and B had normal GM3 ganglioside levels, including patients on low dose regimens and with shorter duration of treatment. In addition, reductions in levels of bis(monoacyl glycerol)-phosphate (BMP) and a potential reduction in levels of glucosylceramide (GlcCer) were observed in Cohort A at Week 24.
High within patient variability in levels of neurofilament (Nf-L), an exploratory biomarker of neuronal structure, was observed pre- and post-treatment. Data from an ongoing observational natural history study conducted by Denali showed a marked increase in mean levels of serum Nf-L over a 4.5- to 6-month period in patients (n=3) who subsequently enrolled in Cohort A of the Phase 1/2 study.
During the 6-month treatment period of the Phase 1/2 study, mean levels of serum and CSF Nf-L in Cohort A (n=5) showed a modest increase. Denali believes that the utility of Nf-L as a treatment response biomarker in MPS II will require further investigation.
The safety profile of DNL310 remained consistent with standard of care enzyme replacement therapy. DNL310 was generally well tolerated with the most common treatment-emergent adverse events being infusion-related reactions (IRRs). IRRs occurred in 12 of 17 (71%) patients: the majority had mild (n=5) or moderate (n=6) IRRs, and 1 patient had severe IRRs.
A total of 3 serious adverse events (SAEs) were reported: 1 previously reported SAE for a patient enrolled in Cohort A based on a mild IRR, and 2 SAEs in a patient enrolled in Cohort B based on severe IRRs. The SAEs resolved, and both patients are continuing in the study. All other treatment-emergent adverse events were mild or moderate.
The study continues without modification following recommendation by an independent data monitoring committee on July 9, 2021.
“DNL310 is our lead program enabled by our blood-brain barrier Transport Vehicle platform, and these data continue to validate the platform’s potential as we advance additional TV-enabled programs toward the clinic,” said Ryan Watts, Ph.D., Denali’s Chief Executive Officer.
“Our DNL310 program exemplifies application of Denali’s core scientific principles to increase likelihood of success by targeting degenogenes, engineering therapeutics to cross the blood-brain barrier, and using biomarkers to inform development. We are encouraged by these interim data and we look forward to continued collaboration with the community to advance MPS II research and DNL310 as a potential treatment for affected individuals and their families.”
Families interested in learning more about Denali’s efforts related to the discovery and development of therapeutics for the potential treatment of Hunter syndrome are invited to visit EngageHunter.com, the Denali Hunter syndrome community engagement website.
Denali will host a webinar for analysts and investors to present the interim data from the Phase 1/2 study of DNL310. The webinar will begin at approximately 11:30 a.m. EDT / 8:30 a.m. PDT on Sunday, July 25, 2021, and will be available on Denali’s corporate website on the Events page under the Investor section and can be accessed by following this link.
SAN FRANCISCO and SUZHOU, China, July 25, 2021 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the first patient has been dosed in a Phase 1 study of IBI321, an anti-PD-1/TIGIT bispecific antibody.
The objective of this open-label, multi-center Phase 1a dose escalation and expansion study is to evaluate the safety, tolerability, potential optimal dosage and preliminary efficacy of IBI321 in patients with advanced malignant tumors whose cancer progressed on standard-of-care treatment. The trial is being conducted in China.
As a bispecific antibody, IBI321 has the potential to enhance efficacy by synergistically targeting both PD-1 and TIGIT. Preclinical studies of IBI321 have shown that the molecule retained the activity of a PD-1 inhibitor and simultaneously suppressed TIGIT to enhance the anti-cancer efficacy.
Professor Baohui Han, Chief of Respiration Department and GCP center of Shanghai Chest Hospital, stated: “Although immune checkpoint inhibitors have shown great efficacy in a variety of tumor types, we still face challenges of primary and secondary drug resistance.
Meanwhile, the efficacy of immune checkpoint inhibitors needs to be further improved. Therefore, the development of the next generation of bispecific antibodies has important clinical value. TIGIT is an important immune checkpoint receptor which plays an important role in tumor immune surveillance. We look forward to the clinical research results of IBI321.